C CRUMPACKER, W HEAGY, G BUBLEY, … - Annals of internal …, 1987 - Am Coll Physicians CLYDE CRUMPACKER, MD; WYRTA HEAGY, Ph.D.; GLENN BUBLEY, MD; JAMES E.
MONROE, Ph.D.; ROBERT FINBERG, MD; SHEILA HUSSEY, RN; LOWELL SCHNIPPER,
MD; DAN LUCEY, MD; TUN HOU LEE, Ph.D.; MARY FRAN MCLANE, MS; MAX ESSEX, ... Cited by 22 - Related articles - All 3 versions
RB Roberts, FB Hollinger, WP Parks, S Rasheed, J … - AIDS, 1990 - journals.lww.com 68 AIDS 1990, Vol 4 No 1 tions were not administered during the 28 weeks of the study. No restrictions
were imposed on other medica- tions such as analgesics, antipyretics, sedatives, and an- tibiotics
for intercurrent non-HIV-related infections. Patient population The study population ... Cited by 17 - Related articles - All 2 versions
[CITATION] Lassa fever: Effective treatment with ribavirin
NJC SNELL - Antiviral chemistry & chemotherapy, 1991 - cat.inist.fr The activity of ribavirin against the human immunodeficiency virus: a review of
laboratory and clinical experience. NJC SNELL Antiviral chemistry & chemotherapy
2:55, 257-263, International Medical Press, 1991. Ribavirine ... Cited by 3 - Related articles
MH Grieco, M Lange, E Buimovici-Klein, MM Reddy, … - Antiviral Res, 1988 - grande.nal.usda.gov Record Detail. Return to previous page, Save: Title: Open study of AL-721 treatment
of HIV-infected subjects with generalized lymphadenopathy syndrome: an eight week
open trial and follow-up. Author: Grieco, MH : Lange, M ... Cited by 9 - Related articles - Cached - All 3 versions
RS Schulof, DM Parenti, GL Simon, H Paxton, … - JAIDS Journal of …, 1990 - journals.lww.com We evaluated the clinical, immunologic, and virologic effects of oral treatment with ribavirin and
isoprinosine for up to 3 months in asymptomatic, HIV-culture-positive homosexual men. Fifteen
consecutive men received isoprinosine 4 g/day (1 g qid), and 800 (9 men) or 1,200 ... Cited by 8 - Related articles - All 2 versions
RB Roberts, OL Laskin, J Laurence, D Scavuzzo, … - Clinical Pharmacology & …, 1987 - nature.com Supported in part by a grant from Viratek, Inc., New York State AIDS Institute (A0129), and National
Institutes of Health General Clinical Research Center (RR47). ... Richard B Roberts MD, Oscar
L Laskin MD * , Jeffrey Laurence MD, Donna Scavuzzo RN, Henry W Murray MD, Young ... Cited by 23 - Related articles - All 3 versions
J Torseth, G Bhatia, S Harkonen, C Child, M … - The Journal of infectious …, 1989 - jstor.org Rifabutin (ansamycin LM 427) is a rifamycin antibiotic with strong inhibitory activity in vitro against
Mycobac- terium avium-intracellulare complex (MAC) and M tuber- culosis [1], It is a spiropiperidyl
derivative of rifamycin S[2]. Several related rifamycins have been shown to inhibit ... Cited by 9 - Related articles - All 3 versions
